Premium
CHL1 expression differentiates Hürthle cell carcinoma from benign Hürthle cell nodules
Author(s) -
Li Wei,
Xia Shujun,
Aronova Anna,
Min Irene M.,
Verma Akanksha,
Scognamiglio Theresa,
Gray Katherine D.,
Ullmann Timothy M.,
Liang Heng,
Moore Maureen D.,
Elemento Olivier,
Zarnegar Rasa,
Fahey Thomas J.
Publication year - 2018
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25214
Subject(s) - medicine , cell , pathology , transcriptome , immunohistochemistry , thyroid nodules , gene , cancer , gene expression , cancer research , biology , malignancy , biochemistry , genetics
Background and Objectives Hürthle cell carcinoma (HCC) is an unusual and relatively rare type of differentiated thyroid cancer. Currently, cytologic analysis of fine‐needle aspiration biopsy is limited in distinguishing benign Hürthle cell neoplasms from malignant ones. The aim of this study was to determine whether differences in the expression of specific genes could differentiate HCC from benign Hürthle cell nodules by evaluating differential gene expression in Hürthle cell disease. Methods Eighteen benign Hürthle cell nodules and seven HCC samples were analyzed by whole‐transcriptome sequencing. Bioinformatics analysis was carried out to identify candidate differentially expressed genes. Expression of these candidate genes was re‐examined by quantitative real‐time polymerase chain reaction (qRT‐PCR). Protein expression was quantified by immunohistochemistry. Results Close homolog of L1 (CHL1) was identified as overexpressed in HCC. CHL1 was found to have greater than 15‐fold higher expression in fragments per kilobase million in HCC compared with benign Hurthle cell tumors. This was confirmed by qRT‐PCR. Moreover, the immunoreactivity score of the CHL1 protein was significantly higher in HCC compared with benign Hürthle cell nodules. Conclusions CHL1 expression may represent a novel and useful prognostic biomarker to distinguish HCC from benign Hürthle cell disease.